Cypherpunk Technologies Inc. Reports Q2 2026 Results; Subsidiary Phase 2 Published

What Happened

• Cypherpunk Technologies Inc. announced its financial results for the quarter ended June 30, 2026 via a press release dated August 12, 2026 (furnished as Exhibit 99.1 to the 8-K). The 8-K states the press release contains the financial details but that the information is not incorporated by reference into other filings.
• On the same day, the company disclosed that its biotechnology subsidiary, Leap Therapeutics, Inc., announced publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti‑DKK1 monoclonal antibody, in the journal Clinical Cancer Research (press release furnished as Exhibit 99.2).

Key Details

• Filing date: August 12, 2026 (Current Report on Form 8-K).
• Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
• Exhibit 99.1: Cypherpunk press release with the quarter’s financial results (not incorporated by reference).
• Exhibit 99.2: Leap Therapeutics press release announcing publication of Phase 2 DeFianCe study results for sirexatamab (DKN-01).

Why It Matters

• Investors should review the company’s August 12 press release (Exhibit 99.1) to see the actual earnings, revenue, cash position and any management commentary, since the 8-K itself references those results but does not restate them.
• Publication of Phase 2 data for Leap Therapeutics’ sirexatamab in a peer‑reviewed journal is a material operational update for Cypherpunk’s biotech subsidiary; it may affect how investors value the company’s pipeline and future milestones or partnership prospects.